Company: PSTV
Filing Date: 2025-04-01
Form Type: PRER14A
Source: 0001140361-25-011649
Chunk: 35

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-01
Form: PRER14A
Chunk 35
---
 2024 Warrants, there would be a greater number of shares of our Common Stock eligible for sale in the public markets. Any such sales, or the anticipation of the possibility of such sales, represents an overhang on the market and could depress the market price of our Common Stock. Finally, the reservation of the shares underlying the May 2024 Warrants precludes the Company from issuing such shares for other purposes including equity financings and we may be unable to raise additional capital as a result.

**Potential Effects of Non-Approval of this Proposal**

The Company is not seeking the approval of stockholders to authorize its entry into the SPEA, as the Company has already done so and the relevant documents are already binding obligations of the Company. The failure of stockholders to approve this proposal will not negate the existing terms of the transactions or the relevant documents, which will remain binding on the Company.

Failure to obtain stockholder approval may materially adversely affect the Company’s future ability to raise equity or debt capital from third parties on attractive terms, if at all, and also risks significantly impairing the operations, assets and ongoing viability of the Company.

Additionally, if approval is not obtained at the Special Meeting, the Company will be obligated to continue to seek stockholder approval at least three times each year until stockholder approval is obtained.

#### Interests of Officers and Directors this Proposal
Our executive officers and directors who hold May 2024 Warrants have an interest in this Proposal No. 4 by virtue of their ownership of the May 2024 Warrants and the benefits conferred by extending the term of the May 2024 Warrants and potential economic gain received upon exercise thereof.

<div align='center'>20</div>

TABLE OF CONTENTS

The following table contains information relating to the ownership of May 2024 Warrants owned by our executive officers and directors, based on information as of April 1, 2025. As of that date, there were 3,093,708 May 2024 Warrants issued and outstanding.

| Name of Beneficial Owner(1) |     | Number of Shares of 
        Common Stock 
 Underlying May 2024 
      Warrants Owned |     | Percent Ownership of   
 Total Number of        
 Shares of Common Stock 
 Underlying Outstanding 
 May 2024 Warrants      |
| Marc H. Hedrick, M.D.(1)    |     |              12,255 |     | *                      |
| Andrew Sims(2)              |     |               4